基底細胞癌(基底細胞上皮腫)治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0534
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:385
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline Review, H2 2019, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline landscape.

Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 14, 7, 8 and 2 respectively.

Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Basal Cell Carcinoma (Basal Cell Epithelioma) – Overview
Basal Cell Carcinoma (Basal Cell Epithelioma) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Basal Cell Carcinoma (Basal Cell Epithelioma) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Basal Cell Carcinoma (Basal Cell Epithelioma) – Companies Involved in Therapeutics Development
4SC AG
Adgero Biopharmaceuticals Holdings Inc
Bayer AG
Biofrontera AG
Biosceptre International Ltd
Bristol-Myers Squibb Co
Cannabis Science Inc
Celgene Corp
Feldan Therapeutics Inc
Galderma SA
Genentech Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Invion Ltd
IO Biotech ApS
Laboratories Ojer Pharma SL
Leo Pharma AS
Mayne Pharma Group Ltd
MediGene AG
Medivir AB
Merck & Co Inc
NuCana Plc
Ono Pharmaceutical Co Ltd
Oshadi Drug Administration Ltd
PellePharm Inc
Phosplatin Therapeutics LLC
QBiotics Ltd
Regeneron Pharmaceuticals Inc
Replimune Ltd
Senhwa Biosciences Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Sichuan Sinovation Bio-technology Co Ltd
Singh Biotechnology LLC
Transgene SA
Basal Cell Carcinoma (Basal Cell Epithelioma) – Drug Profiles
Basal Cell Carcinoma (Basal Cell Epithelioma) – Dormant Projects
Basal Cell Carcinoma (Basal Cell Epithelioma) – Discontinued Products
Basal Cell Carcinoma (Basal Cell Epithelioma) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by 4SC AG, H2 2019
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H2 2019
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Bayer AG, H2 2019
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H2 2019
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H2 2019 (Contd..1), H2 2019
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, H2 2019

【掲載企業】

4SC AG
Adgero Biopharmaceuticals Holdings Inc
Bayer AG
Biofrontera AG
Biosceptre International Ltd
Bristol-Myers Squibb Co
Cannabis Science Inc
Celgene Corp
Feldan Therapeutics Inc
Galderma SA
Genentech Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Invion Ltd
IO Biotech ApS
Laboratories Ojer Pharma SL
Leo Pharma AS
Mayne Pharma Group Ltd
MediGene AG
Medivir AB
Merck & Co Inc
NuCana Plc
Ono Pharmaceutical Co Ltd
Oshadi Drug Administration Ltd
PellePharm Inc
Phosplatin Therapeutics LLC
QBiotics Ltd
Regeneron Pharmaceuticals Inc
Replimune Ltd
Senhwa Biosciences Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Sichuan Sinovation Bio-technology Co Ltd
Singh Biotechnology LLC
Transgene SA

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[基底細胞癌(基底細胞上皮腫)治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆